(Q38066620)

28 August 2017

1 reference

title

Clinical pharmacokinetics of second generation antisense oligonucleotides (English)

1 reference

28 August 2017

1 reference

Rosie Z Yu

1

1 reference

28 August 2017

John S Grundy

series ordinal

2

1 reference

28 August 2017

Richard S Geary

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

12 December 2012

1 reference

Expert Opinion on Drug Metabolism & Toxicology

28 August 2017

1 reference

28 August 2017

9

1 reference

28 August 2017

2

1 reference

28 August 2017

169-182

1 reference

Gene inhibition using antisense oligodeoxynucleotides

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

The influence of antisense oligonucleotide-induced RNA structure on Escherichia coli RNase H1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Oligonucleotidic therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Antisense oligonucleotides for the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Quantitation of phosphorothioate oligonucleotides in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

On the volume of distribution at steady state and its relationship with two-compartmental models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

In vitro metabolic stabilities and metabolism of 2'-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Membrane transporters in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Oral delivery of antisense oligonucleotides in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.737320

10.1517/17425255.2013.737320

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference